Clinical Trial Update: Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial assessing gefitinib with anlotinib or placebo in newly diagnosed EGFR-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lung Cancer, Nonsmall Cell | Phase 3 | Status: UNKNOWN